Abliva AB (NEVPF)
0.01
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Abliva Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -18.42K% |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | -81.03K% |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | -76.81K% |
| September 30, 2021 | -41.00K% |
| June 30, 2021 | -168.4K% |
| March 31, 2021 | |
| December 31, 2020 | -11.77K% |
| September 30, 2020 | |
| June 30, 2020 | -20.94K% |
| March 31, 2020 | -206.7K% |
| December 31, 2019 | -55.32K% |
| September 30, 2019 | |
| June 30, 2019 | -24.43K% |
| March 31, 2019 | |
| December 31, 2018 | -297.0K% |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 |
| Date | Value |
|---|---|
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | -61.46K% |
| December 31, 2016 | -92.66K% |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | -624.4% |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | -48.25% |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | -53.76% |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| December 31, 2011 | -47.48% |
| September 30, 2011 |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-206.7K%
Minimum
Mar 2020
-11.77K%
Maximum
Dec 2020
-75.60K%
Average
-55.32K%
Median
Dec 2019
Profit Margin (Quarterly) Benchmarks
| Oncopeptides AB | -1.45K% |
| BioInvent International AB | -761.8% |
| Hansa Biopharma AB | -213.3% |
| BioArctic AB | -137.3% |
| Camurus AB | 26.97% |